Cagrilintide Dosage Guide

Cagrilintide is a synthetic, long-acting analog of amylin — a hormone co-secreted with insulin from pancreatic beta cells. Amylin plays key roles in slowing gastric emptying, promoting satiety, and suppressing glucagon secretion. Cagrilintide has been engineered for once-weekly subcutaneous administration.

In clinical trials, cagrilintide has demonstrated significant weight loss both as monotherapy and in combination with semaglutide 2.4 mg (the combination is designated CagriSema). The REDEFINE Phase 3 trial program showed that CagriSema achieved approximately 25% weight loss — exceeding semaglutide alone — by targeting two complementary satiety pathways (amylin and GLP-1).

Dosing is based on Phase 2 and Phase 3 clinical trial protocols:

Phase 2 data showed dose-dependent weight loss: 6.0% (0.3 mg), 6.8% (1.2 mg), and 10.8% (4.5 mg) as monotherapy over 26 weeks. The CagriSema combination produced approximately 15.6% weight loss at 32 weeks in Phase 2.

Cagrilintide is administered once weekly by subcutaneous injection:

• Same day each week: Inject at any time, with or without food.
• Dose escalation: Increase every 4 weeks per the titration schedule.
• CagriSema: Both components are co-formulated in a single injection device in clinical trials.

Duration: Clinical trials have evaluated treatment durations of 26–68 weeks. Like other anti-obesity medications, weight regain is expected upon discontinuation, suggesting ongoing treatment is necessary for maintained benefit.

Cagrilintide is currently available only through clinical trials as pre-filled devices. For compounded research formulations:

• Step 1: Swab vial stoppers with alcohol.
• Step 2: Reconstitute per vial specifications with BAC water.
• Step 3: Direct stream along glass wall.
• Step 4: Gently swirl until clear.
• Step 5: Store at 2–8°C.

Inject subcutaneously into the abdomen, thigh, or upper arm. Rotate injection sites weekly.

• 0.25–1.2 mg: Nausea (10–20%), injection site reactions, mild GI symptoms.
• 2.4–4.5 mg: Nausea (25–35%), vomiting (8–12%), diarrhea, decreased appetite. Most events occur during titration and are mild-to-moderate.
• CagriSema: GI side effects are similar to semaglutide 2.4 mg alone, suggesting the combination does not significantly increase GI burden.

Cagrilintide is an investigational compound in Phase 3 clinical trials. It is NOT FDA-approved.

As an amylin analog, cagrilintide may affect gastric motility and glucose regulation. Monitor for hypoglycemia when combined with insulin or sulfonylureas. Only participate in cagrilintide research through authorized clinical trials. Consult a healthcare provider for guidance.